| Pyelonephritis
Vabomere vs Zerbaxa
Side-by-side clinical, coverage, and cost comparison for pyelonephritis.Deep comparison between: Vabomere vs Zerbaxa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZerbaxa has a higher rate of injection site reactions vs Vabomere based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zerbaxa but not Vabomere, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Vabomere
Zerbaxa
At A Glance
IV infusion
Every 8 hours
Carbapenem + beta-lactamase inhibitor
IV infusion
Every 8 hours
Cephalosporin/beta-lactamase inhibitor
Indications
- Complicated urinary tract infection
- Pyelonephritis
- Peritonitis
- Urinary tract infection
- Pyelonephritis
- Hospital acquired pneumonia
- VABP
Dosing
Complicated urinary tract infection, Pyelonephritis 4 grams (meropenem 2 grams and vaborbactam 2 grams) IV infusion over 3 hours every 8 hours for up to 14 days in patients with eGFR >=50 mL/min/1.73m2; dose adjustment required for eGFR <50 mL/min/1.73m2 (2 grams every 8 hours for eGFR 30-49, 2 grams every 12 hours for eGFR 15-29, 1 gram every 12 hours for eGFR <15).
Peritonitis 1.5 g IV every 8 hours over 1 hour for 4 to 14 days, used in conjunction with metronidazole 500 mg IV every 8 hours; pediatric patients: 30 mg/kg up to 1.5 g every 8 hours for 5 to 14 days.
Urinary tract infection, Pyelonephritis 1.5 g IV every 8 hours over 1 hour for 7 days; pediatric patients: 30 mg/kg up to 1.5 g every 8 hours for 7 to 14 days.
Hospital acquired pneumonia, VABP 3 g IV every 8 hours over 1 hour for 8 to 14 days in adult patients 18 years and older.
Contraindications
- Known hypersensitivity to any component of VABOMERE (meropenem and vaborbactam) or to other drugs in the same class
- Demonstrated anaphylactic reactions to beta-lactam antibacterial drugs
- Known serious hypersensitivity to components of ZERBAXA (ceftolozane and tazobactam), piperacillin/tazobactam, or other members of the beta-lactam class
Adverse Reactions
Most common (>=3%) Headache, phlebitis/infusion site reactions, diarrhea
Serious Hypersensitivity reactions, seizures, rhabdomyolysis, Clostridioides difficile-associated diarrhea, breakthrough seizures (valproic acid interaction), thrombocytopenia, neuromotor impairment
Postmarketing Rhabdomyolysis, drug-induced liver injury (DILI) including hepatitis and liver failure
Most common (>=5%) Nausea, diarrhea, headache, pyrexia
Serious Hypersensitivity reactions, Clostridioides difficile-associated diarrhea, intracranial hemorrhage, renal impairment/renal failure, hepatic transaminase increased
Pharmacology
Meropenem is a penem antibacterial that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins in gram-positive and gram-negative bacteria; vaborbactam is a cyclic boronic acid, non-suicidal beta-lactamase inhibitor that protects meropenem from degradation by serine beta-lactamases, including Klebsiella pneumoniae carbapenemase (KPC), without intrinsic antibacterial activity.
Ceftolozane is a cephalosporin antibacterial that inhibits bacterial cell wall biosynthesis by binding to penicillin-binding proteins (PBPs); tazobactam is an irreversible beta-lactamase inhibitor that extends ceftolozane activity against beta-lactamase-producing organisms.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Vabomere
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (0/12)
Zerbaxa
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (6/12) · Qty limit (0/12)
UnitedHealthcare
Vabomere
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Zerbaxa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Vabomere
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Zerbaxa
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Vabomere.
No savings programs available for Zerbaxa.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
VabomereView full Vabomere profile
ZerbaxaView full Zerbaxa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.